Greg Schiffman, chief financial officer for Affymetrix, has been named to the board of directors of Impac Medical Systems of Mountain View, Calif., the company said this week. Schiffman, a CPA, holds a BS in accounting from DePaul University, and an MBA from Northwestern University.
Ed Hurwitz has resigned as interim chief executive officer of Aclara Biosciences of Mountain View, Calif. The former CFO of Affymetrix turned in notice on Feb. 21, saying he was leaving to concentrate full-time on his job as venture partner for Alta Partners, a San Francisco venture capital firm. Hurwitz will continue to serve on Aclara’s board of directors, a position he has held since July. His resignation follows a downsizing at Aclara and follows by three months the resignation of former CEO
Limber and fellow board member André Marion will serve as an operating committee of the board to guide the company’s operations.
Robert Linhardt has been appointed to a senior constellation chair in biocatalysis and metabolic engineering at Rensselaer Polytechnic Institute in Troy, NY. Linhardt is professor of chemistry, medicinal and natural products chemistry and chemical and biochemical engineering at the University of Iowa. He is known for his work in therapeutic agents, from small molecules to polymeric materials. He will begin at Rensselaer in the fall. The constellation is a Rensselaer construct for a multidisciplinary team of faculty and graduate students with a focus on a research field.. Kindhard holds a PhD in organic chemistry from Johns Hopkins and a BS in chemistry from Marquette University.
George Poste was named to the Monsanto board of directors, replacing Philip Needleman, the chief scientific officer and senior vice president of Pharmacia. Poste is the CEO of Health Technology Networks, a consultancy in genomics and healthcare computing. Poste was formerly CSO and CTO, and president of R&D, for SmithKline Beecham. He is a member of the defense science board of the Department of Defense and is the chairman of the group’s task force on bioterrorism.
Glenn Walker was named director of production for Aviva Biosciences of San Diego. Walker was a previously an independent consultant in software and equipment validation for biotechnology firms.